Posted by Michael Wonder on 14 Oct 2023
US FDA approves Opdivo (nivolumab) as adjuvant treatment for eligible patients with completely resected stage IIB or stage IIC melanoma
13 October 2023 - In the Phase 3 CheckMate-76K trial, Opdivo demonstrated a statistically significant improvement in recurrence-free survival compared to placebo.
BMS today announced that Opdivo (nivolumab) was approved by the US FDA for the adjuvant treatment of adult and paediatric patients 12 years and older with completely resected stage IIB or IIC melanoma, expanding upon the existing adjuvant indication for Opdivo and further reinforcing the company’s legacy of providing treatment options for melanoma patients.
